Tarsus Pharmaceuticals dips on planned $100 million equity raise

Tarsus Pharmaceuticals

12/03/2025 20:54

** Tarsus Pharmaceuticals' TARS.O shares fall 1.8% to $46.25 in extended trade

** Co announces commencement of proposed $100 million public offering

** TARS plans to use the proceeds to boost the commercialization of its drug XDEMVY and to develop its product pipeline, among other purposes

** Goldman Sachs, BofA Securities, Barclays and Oppenheimer are the joint book-running managers for the offering

** TARS had ~38.3 million shares outstanding as of December 31, giving it a $1.8 billion market cap

** As of last close, TARS stock down 14.9% YTD, after more than doubling in 2024

 (Reporting by Arasu Kannagi Basil in Bengaluru)

 ((ArasuKannagi.Basil@thomsonreuters.com))